Market News AIOpen the app

Johnson & Johnson said its TREMFYA drug showed strong results in a study for treating psoriatic arthritis.

TrialRead the original at prnewswire.com
Good for JNJ

Johnson & Johnson said TREMFYA improved axial symptoms, spinal pain, and stiffness, and reduced joint inflammation versus placebo at Week 24. No new safety signals appeared, but the report describes a possible treatment option, not a change in sales or approval.

JNJ · Johnson & Johnson

AI read · Good for JNJ

The AI's read

These findings give J&J evidence that TREMFYA may help a specific group of people with psoriatic arthritis. The symptom gains and lack of new safety signals support the drug. The report describes a possible treatment option, but does not report a change in sales or approval.

Get alerts for JNJ

Follow Johnson & Johnson (JNJ) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for JNJ
Free on the App Store and Google Play, or on the web.